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ABSTRACT (250 words max)  
Background Pseudohypoparathyroidism (PHP) is a rare heterogeneous genetic disorder 
characterized by end-organ resistance to parathyroid hormone (PTH) due to partial deficiency 
of the α subunit of the stimulatory G protein (Gsα), encoded by the GNAS gene. 
Heterozygous inactivating GNAS mutations lead to PHP type Ia (PHP-Ia) when maternally 
inherited or pseudo-pseudohypoparathroidism (PPHP) if paternally derived. Both diseases 
feature typical physical traits identified as Albright’s hereditary osteodystrophy (AHO), in the 
presence or absence of multihormone resistance, respectively. GNAS mutations are detected 
in 60-70% of affected subjects and most patients/families harbor private mutations. No 
genotype-phenotype correlation has been found to date, but these data come from small series 
of patients. Methods We investigated by direct sequencing Gsα-coding GNAS exons (exons 
1-13) in a large panel of PHP-Ia/PPHP patients collected over the past decade in the two 
Italian referring centers for PHP and we next collected all previously reported mutations of 
the gene. Results Of 48 patients carrying GNAS mutations, in 25 cases we detected 17 known 
alterations while in 23 patients we identified 16 novel mutations. No apparent correlation was 
found between clinical/biochemical data and results of molecular analysis. Furthermore, we 
summarized the current knowledge of GNAS molecular pathology and reported all known and 
novel mutations in the GNAS LSDB (Locus Specific DataBase). Conclusion These results 
further expand the spectrum of GNAS mutations associated with PHP/PPHP and underline the 
importance of identifying such genetic alterations to supplement clinical evaluation and 
genetic counselling.  
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INTRODUCTION 
Pseudohypoparathyroidism (PHP) is a rare heterogeneous genetic disorder 
characterized by hypocalcemia and hyperphosphatemia due to end-organ resistance to 
parathyroid hormone (PTH). [1]  Patients affected with its most investigated subtype,  PHP 
type Ia (PHP-Ia) (OMIM 103580), often present with additional hormonal resistances (TSH, 
GHRH, calcitonin and gonadotropins) and show characteristic physical features collectively 
termed Albright’s hereditary osteodystrophy (AHO) that include short stature, obesity, round 
face, brachydactyly, heterotopic ossifications and intellectual disability. Patients showing the 
physical features of AHO without evidence of hormone resistance were described by Albright 
and colleagues 10 years after their first report of PHP. This syndrome, which was termed 
pseudo-pseudohypoparathyroidism (PPHP; OMIM 612463) may be present either in kindreds 
in which PHP is present or as an isolated defect (in this case it is named AHO-like syndrome, 
OMIM 600430).[1]   
PHP exemplifies a quite unusual form of hormone resistance because the underlying 
molecular defect affects the alpha subunit of the stimulatory guanine-nucleotide binding 
protein (Gsα), which has a key role in downstream signaling pathway, rather than the 
hormone receptor itself. G proteins are so called because they bind to guanine nucleotides 
and belong to a family of proteins (GTP-binding proteins) able to bind and hydrolyze GTP. 
They are heterotrimers consisting of three distinct subunits   and ) and the functional 
properties of each protein mostly depends on the specific  subunit.[2] 
PHP-Ia and PPHP are caused by heterozygous inactivating mutations located within 
the GNAS gene inherited from the mother or the father, respectively. This pattern of 
inheritance is consistent with tissue-specific imprinting of GNAS paternal allele, as 
demonstrated in selected human organs displaying a parent-of-origin difference in hormone 
responsiveness.[3,4] The human GNAS gene, which encodes also but not only the Gsα 
protein, maps to 20q13 and its cDNA spans a region of about 1.2 kb. The first GNAS 
mutation responsible for PHP-Ia was described in 1990 by Patten et al..[5] To date, 
numerous different mutations have been identified in all of the 13 exons, including exon 3, 
where mutations would be expected to have little or no clinical consequence as it undergoes 
physiological alternative splicing.[6] Most of the genetic defects described are associated to a 
single kindred, though a single mutational hot spot has been so far identified within exon 
7.[7-9] Missense mutations and small insertions/deletions predominate, but nonsense 
mutations and point mutations that alter translation initiation or determinate aberrant mRNA 
splicing have also been documented. [10-31] In families in which PHP-Ia and PPHP coexist, 
GNAS mutations are detected in all the affected members, i.e. members affected with either 
PHP-Ia or PPHP.[19,32]  
Here we report clinical, biochemical, and molecular analysis of 48 patients affected 
with PHP-Ia or PPHP carrying heterozygous GNAS mutations. In 25 cases we detected 17 
already reported mutations while in 23 patients we identified 16 novel mutations. Moreover, 
a review of all reported mutations was performed in order to look for genotype/phenotype 
correlations as well as for the existence of novel mutational hot spots. These results further 
expand the spectrum of GNAS mutations associated with PHP/PPHP and underline the 
importance of identifying such genetic alterations to supplement both clinical evaluation of 
patients and genetic counseling of their families.  
 
MATERIALS AND METHODS 
Patients recruitment and evaluation 
This series includes 48 patients (29 females and 19 males), all born from healthy, non-
consanguineous Caucasian parents. The inclusion criteria was the presence of a clinical 
diagnosis of PHP-Ia or PPHP, based upon the presence/absence of PTH resistance (i.e. 
hypocalcemia, hyperphosphatemia and raised serum PTH levels) together with at least two of 
the six AHO manifestations: brachydactyly (shortening of fourth and/or fifth metacarpals) 
[31], short stature (height below the 3th percentile for chronological age), obesity (BMI >30 
kg/m2 in adults and >97th centile in children), round face, subcutaneous ossifications (either 
clinically evident or at X-ray), and mental retardation.[1] Of the two AHO signs required, 
either brachydactyly or heterotopic ossifications had to be present in order to define AHO in 
a given patient. Diagnosis was made at ages ranging between 1 and 34 year-old. The majority 
of PHP-Ia patients (n=39) also showed resistance to TSH, documented by raised serum TSH 
levels, absence of anti-thyroid antibodies and presence of a normal thyroid scan (data not 
shown). Resistance to gonadotropins and/or GHRH was also documented in a subset of 
patients (8 and 9, respectively), but it is to note that not all patients were screened for these 
resistances. Clinical details are shown in table 1. Informed consent was obtained from all 
patients included in the study. 
 
Table 1 Clinical characteristics of patients carrying GNAS mutations included in the present study.  
pt 
ID  
gender  age  rPTH  rTSH  Ob  Fr  MR  Br  EO  SS  PHP  ex/IVS  DNA mutation  
42  M  18  
  
         X  X     Ia  5'UTR+ex1  
c.1-10_2delCGCCGCC 
GCCAT  
33  M  2  
  
X  X  X  X        Ia  ex1  c.7T>C  
52  M  2  
  
   X  X  X        Ia  ex1  c.21_22insT  
34  F  2  
  
X  X        X     Ia  ex1  c.85C>T  
35a  F  4  
  
X  X  X     X     Ia  ex1  c.85C>T  
35b  M  4  
  
X  X  X  X        Ia  ex1  c.85C>T  
36  F  2  
  
            X  X  PPHP  ex1  c.85C>T  
37  F  2  
  
X  X  X  X     X  PPHP  ex1  c.97G>A  
38  F  0.5  
  
X  X     X  X  X  PPHP  ex1  c.103C>T  
39  M  9  
  
   X  X  X  X  X  Ia  ex1  c.103C>T  
40a  M  5  
  
            X     Ia  ex1  c.103C>T  
40b  M  5  
  
         X  X     Ia  ex1  c.103C>T  
41  M  13  
  
   X     X  X     Ia  ex1  c.110delA  
3  M  5  
  
      X  X        Ia  ex1  c.112delC  
5  F  20  
  
   X  X  X  X  X  Ia  ex4  c.308C>A  
6  M  34  
  
X  X  X  X     X  Ia  ex4  c.311T>C  
8  M  4  
  
X  X  X  X        Ia  ex5  c.347_348insT  
10  F  2  
  
X  X  X  X  X     Ia  ex5  c.348_349insC  
11  M  2  
  
   X     X  X     Ia  ex5  c.348_349insC  
45  F  1  
  
   X  X  X        Ia  ex5  c.366delC  
46  F  4  
  
X  X     X        Ia  ex5  c.421_422delTT  
12  M  23  
  
      X  X     X  PPHP  ex6  c.478G>A  
13  F  9  
  
X  X  X  X        Ia  ex6  c.481C>T  
14  F  10  
  
   X     X     X  Ia  ex6  c.496C>T  
47  M  9  
  
X  X  X  X     X  Ia  ex6  C.523_524delTG  
17  F  8  
  
X  X     X        Ia  ex7  c.568_571delGACT  
18  F  14  
  
         X        PPHP  ex7  c.568_571delGACT  
20  F  1  
  
X           X     Ia  ex7  c.568_571delGACT  
21  M  1  
  
X  X        X     Ia  ex7  c.568_571delGACT  
22  F  5  
  
X  X  X  X  X  X  Ia  ex7  c.568_571delGACT  
24a  F  13  
  
X  X  X  X     X  Ia  ex9  c.694C>T  
24b  F  13  
  
X  X  X  X     X  Ia  ex9  c.694C>T  
25  F  19  
  
X  X     X     X  Ia  ex10  c.728C>T  
48a  F  7  
  
         X        Ia  ex10  c.742G>C  
48b  F  7  
  
         X        Ia  ex10  c.742G>C  
49  M  12  
  
X  X  X  X        Ia  ex10  c.806A>G  
26  F  5  
  
X  X  X  X        Ia  ex11  c.863_864delTG  
27  F  2  
  
X  X     X        Ia  ex12  c.1009C>T  
28  M  11  
  
X  X     X     X  Ia  ex12  c.1009C>T  
50  F  2  
  
X  X        X     Ia  ex12  c.1021_1024delTTCA  
51  F  17    X  X  X  X  X  X  Ia  ex12  
c.1021_1022insACGCGTGACCC 
GGGCCAAGTACT  
29  F  20  
  
      X  X  X  X  PPHP  ex13  c.1110_1111delTG  
53a  F  7  
  
   X     X     X  Ia  ex 13  c.1153C>T  
53b  M  5  
  
                  Ia  ex 13  c.1153C>T  
43  F  10  
  
X  X     X  X  X  Ia  IVS1  c.139+1T>A  
4  M  7  
  
            X     Ia  IVS2  c.212+2delAAGT  
44  F  4  
  
         X        Ia  IVS3  c.258+1G>A  
54  F  9  
  
         X  X     PPHP  IVS5  c.435+1G>A  
Legend: age (years at diagnosis), PTH levels (PTH resistance defined by PTH > 65 mU/L), TSH levels (TSH 
resistance defined by TSH > 3.9 pg/mL), Ob (obesity), RF (round face),  MR (mental retardation), Br 
(brachydactyly), SC (subcutaneous ossifications), SS (short stature).  
 
 
Sequencing analysis of the GNAS gene 
Genomic DNA was extracted from peripheral blood leukocytes by Nucleon BACC2 
genomic DNA purification kit (GE Healthcare, Piscataway, NJ, USA) according to the 
manufacturer's instructions. The DNA obtained was amplified by PCR for GNAS 1-13 exons 
and flanking intronic sequences (ENSEMBL ID: ENSG00000087460), using specific primers 
[11,34]. Direct sequencing of the amplicons was performed with the AmpliTaq BigDye 
Terminator kit and 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA), as 
previously described.[11,34]  
Mutation nomenclature and literature review 
The mutation nomenclature used in the present paper follows the guidelines indicated 
by Human Genome Variation Society (HGVS).[35] Nucleotide and protein numbering are 
based on GNAS LRG sequence format created by Leiden Open Variation Database (LOVD at 
http://chromium.liacs.nl/LOVD2/home.php?select_db=GNAS). LRG reference sequences is 
not subject to versioning and is annotated with all transcripts and encoded proteins essential 
for variant description. Nucleotide 1 numbering reflects cDNA numbering with position +1 
referring to the A of the translation initiation codon. Mutation description at the protein level 
considers the initiator methionine as codon 1. We performed an electronic search in public 
locus-specific databases HGMD (http://www.hgmd.org/) and LOVD in order to collect all 
reported pathogenic variants. Cases were cross-referenced and the correctness of descriptions 
was checked in order to avoid duplications.    
Assessment of pathogenicity 
In the present study, in agreement with the view that the molecular basis for PHP type 
I is represented by Gs haploinsufficiency, we classified all novel nonsense mutations, 
frameshift mutations and mutations of the first two bases of canonical intron splice sites as 
deleterious. A nonsense mutation results in a premature stop codon in the transcribed mRNA 
and in a truncated, incomplete and usually nonfunctional protein product. Moreover, 
nonsense-mediated mRNA decay has been also associated with GNAS nonsense mutations in 
PHP-Ia.[19] A frameshift mutation (also called a reading frame shift) is a genetic mutation 
caused by insertions or deletions of a number of nucleotides that is not evenly divisible by 
three and, due to the triplet nature of gene expression by codons, it changes the reading 
frame, resulting in a completely different translation from the original. The earlier in the 
sequence the defect occurs, the more altered the protein produced is. Nucleotide signals at the 
splice sites precisely guide the enzymatic machinery in the removal of intronic sequences 
when the pre-mRNA is processed to form the mRNA so that, when mutated, the intron is 
retained as part of the final RNA molecule and the translation of its sequence alters the 
sequence of the protein product.  
As for novel missense mutations, we performed an in silico analysis using different 
computer generated algorithms in order to predict the possible effect in vivo. Indeed,  
bioinformatic tools allowed to evaluate the impact of genetic mutations on the protein 
product according to the structure of the GNAS gene and Gsα structural domains. In 
particular, we used the following algorithms: 1. Polymorphism phenotyping program 2, 
Polyphen2 (available at http://genetics.bwh.harvard.edu/pph2/), an online tool able to predict 
the impact of an aminoacid substitution on both structure and function of human proteins, 
based on the combined analysis of protein multiple sequence alignment and protein structural 
and functional attributes; 2. Sort Intolerant From Tolerant human Protein, SIFT human 
Protein program (available at http://sift.jcvi.org/www/SIFT_enst_submit.html), that provides 
predictions for tolerated and non-tolerated mutations at selected amino acids in Ensembl 
transcripts with an assigned ENSP number, through protein sequence alignments of multiple 
species.  
Data analysis 
A paired two-tailed Student’s t test was used to detect the significance between two 
series of data. p<0.05 was accepted as statistically significant. 
 
RESULTS  
Mutation analysis 
Sequencing analysis of GNAS Gsα-coding exons identified 33 heterozygous loss of 
function mutations in 48 patients affected with either PHP-Ia or PPHP (tables 2 and 3, figure 
1). These sequence abnormalities were demonstrated to co-segregate with the disorder in the 
few familial cases included in this series (pts 3, 13, 24a, 24b, 26, 35a, 35b, 38, 40a, 40b, 45, 
48a, 48b, 53a and 53b) and to be absent as common polymorphisms in 100 unrelated normal 
individuals. Of theses, 17 were already reported mutations, of which 9 were 
missense/nonsense point mutations, 6 were small insertions or deletions causing frameshift 
and 2 were mutations of canonical splice acceptor or donor sites (for a brief description of 
these known variants see table 2).  
 
Table 2 GNAS mutations described in literature and detected in patients included in the 
present study.  
Pt ID inheritance 
site of 
mutation 
DNA sequence 
change 
amino acid change 
Type of 
mutation 
HGMD® 
accession 
number 
3 ♀ ex1 c.112delC p.(Arg38Glyfs*19) FS CD002905 
4 n.a.  IVS2 c.212+2delAAGT p.(?)  SP CD031052 
5 n.a.  ex4 c.308C>A p.(Ala103Glu) MS CM013729 
6 n.a.  ex4 c.311T>C  p.(Ile104Thr)  MS CM002271 
8 de novo ex5 c.347_348insT p.(Pro116Profs*24) FS CI020091 
10-11 n.a.  ex5 c.348_349insC p.(Val118Argfs*22) FS CI031096 
54  n.a.  IVS5  c.435+1G>A  p.(?)  SP  CS941495  
12 n.a.  ex6 c.478G>A p.(Val160Met) MS CM020280 
13 ♀ ex6 c.481C>T  p.(Arg161Cys)  MS CM002273 
14 n.a.  ex6 c.496C>T  p.(Arg166Cys)  MS CM930348 
17-18-20-
21-22  
n.a.  ex7 c.568_571delGACT p.(Asp190Metfs*13) FS CD920862 
24a-24b ♀ ex9 c.694C>T p.(Arg232Cys) MS CM013732 
25 n.a.  ex10 c.728C>T p.(Thr243Ile) MS CM031194 
26 ♀ ex11 c.863_864delTG p.(Val288Aspfs*11) FS CD002906 
27-28 n.a.  ex12 c.1009C>T p.(Arg337Trp) MS CM013736 
29 n.a.  ex13 c.1110_1111delTG  p.(Thr370Thrfs*11) FS CD002504 
53a-53b  ♀ ex13 c.1153C>T  p.(Gln385X)  NS  CM056331  
Legend: ♀, maternal; ♂, paternal; de novo, no parental inheritance; n.a., parents not available, 
ex, exon; IVS, intron, MS, missense; NS, nonsense; FS, frameshift; SP, splice site. 
 
The remaining 16 mutations were novel to the literature and distributed as following 
(see also table 3): 
Mutations in the GTPase domain  
Both exons 1 and 2 encode the functional domain with GTPase activity, so that 
mutations in this region are expected to affect the ability to bind or hydrolyze GTP. 
Seven different novel mutations detected in 11 patients were located in exon 1 (3 
frameshift, 2 nonsense and 2 missense). Patient 52 (c.21_22insT) was found to carry the 
insertion of a thymine that generates a premature stop codon (p.Lys8X). A de novo frameshift 
mutation detected in patient 41 (c.110delA) causes the substitution of Tyr37Ser and the 
creation of a premature stop codon. Patient 42 displayed a de novo 12-bp deletion in the 
region encompassing the translation start site (c.1-10_2delCGCCGCCGCCAT), causing the 
loss of the ATG initiation codon. Four subjects (pts 35a and 35b, who are brother and sister, 
and 2 unrelated cases, pts 34 and 36) presented the nonsense mutation Gln28X caused by 
c.85C>T transition. The nonsense mutation p.Gln35X, due to c.103C>T transition, was found 
in 4 patients belonging to 3 families (paternal inheritance in pts 40a and 40b, maternal 
inheritance in pt 38 and de novo in pt 39).  
As for missense mutations, the first is a c.7T>C transition (pt 33), resulting in the 
substitution of the hydrophobic amino acid cysteine in position 3 with the hydrophilic 
arginine (p.Cys3Arg). This highly conserved amino acidic residue has an important role in 
membrane anchoring, undergoing conversion to S-palmitoyl cysteine. Protein S-acylation is a 
major post-translational modification and a well-recognized determinant of protein function 
and localization. The mutations is predicted to be deleterious according to bioinformatic 
analysis. 
In patient 37 we detected the c.97G>A transition resulting in the substitution at 
position 33 of an acid aspartic residue (negatively charged) with an asparagine (non polar). 
According to the bioinformatic prediction this mutation (p.Asp33Asn) is probably damaging 
and, although this residue is not highly conserved, no known species carries an asparagines at 
this position.  
Mutations in the adenylate cyclase interaction domain  
Patient 45 displayed a single base deletion in exon 5 (c.366delC) which results in the 
creation of a premature stop codon 11 amino acids downstream Asn122. Patient 46 showed a 
de novo 2-bp deletion in exon 5 (c.421_422delTT), that determines the creation of a 
premature stop codon instead of wild-type Phe141. 
Mutations in domains involved in protein structure/conformation  
In patient 47 we found a 2-bp deletion in exon 6 with consequent formation of a 
premature stop codon 14 amino acids downstream Cys175 (c.523_524delTG). Sisters 48a 
and 48b maternally inherited a missense mutation (c.742G>C; p.Val248Leu) in exon 10. The 
pathogenic effect of this mutation was confirmed by computer investigations, who predicted 
a damaging effect. A last novel missense mutation, c.806A>G, was also detected within exon 
10 (pt 49), determining the substitution p.Glu269Gly. A damaging effect of this substitution 
was predicted and further validated by the high conservation of this residue.  
Mutations in the GPCR interaction domain  
Patient 50 had a de novo 4-bp deletion in exon 12 (c.1021_1024delTTCA), with 
generation of a premature stop codon 5 downstream Phe341. Finally, a de novo insertion of 
23-bp in exon 12 was detected in patient 51 
(c.1021_1022insACGCGTGACCCGGGCCAAGTACT), also generating a stop codon at Phe 
341. 
Intronic mutations  
In patienst 43 and 44 we detected splice site mutations in intron 1 (c.139+2T>A) and 
in intron 3 (c.258+1G>A), respectively. The T>A transversion at intron 1 donor splice site 
likely results in the inclusion of intron 1 in the transcript, with consequent introduction of 154 
additional amino acids before a stop codon. Similarly, transition G>A found in patient 44 
likely causes the inclusion of intron 3 and the creation of a premature stop codon with no 
additional amino acids. 
 
Table 3 Novel GNAS mutations detected in patients included in the present study.  
Pt ID inheritance 
site of 
mutation 
DNA sequence change amino acid change 
Type of 
mutation 
33   ex1 c.7T>C p.(Cys3Arg) MS 
52 n.d. ex1 c.21_22insT p.Lys8X  FS/NS  
34-35a-
35b-36 
♀ [35a;35b]  ex1 c.85C>T p.(Gln29X) NS 
37 n.d. ex1 c.97G>A p.(Asp33Asn) MS 
38-39-
40a-40b 
♀[38], de 
novo [39], 
♂[40a;40b]  
ex1 c.103C>T p.(Gln35X) NS 
41 de novo ex1 c.110delA p.(Tyr37Serfs*15) FS 
42 de novo 5'UTR+ex1 c.1-10_2delCGCCGCCGCCAT p.(0?)  FS 
43 n.d. IVS1 c.139+1T>A p.(?)  SP 
44 n.d. IVS3 c.258+1G>A p.(?)  SP 
45 ♀ ex5 c.366delC p.(Asn122Asnfs*12) FS 
46 de novo ex5 c.421_422delTT p.(Phe141X) NS 
47 n.d. ex6 C.523_524delTG p.(Cys175Cysfs*14) FS 
48a-48b ♀ ex10 c.742G>C p.(Val248Leu) MS 
49 n.d. ex10 c.806A>G p.(Glu269Gly) MS 
50 de novo ex12 c.1021_1024delTTCA p.(Phe341Phefs*5) FS 
51 de novo ex12 
c.1021_1022insACGCGTGACCC
GGGCCAAGTACT 
p.(Phe341Tyrfs*3) FS 
Legend: ♀, maternal; ♂, paternal; de novo, no parental inheritance; n.a., parents not available, 
ex, exon; IVS, intron; MS, missense; NS, nonsense; FS, frameshift; SP, splice site. 
 
 
Review of the literature and LOVD update 
We next reviewed all GNAS loss-of-function mutations associated to PHP-Ia and 
PPHP published in the two main public locus-specific databases (HGMD and LOVD). To 
avoid duplications, we  cross-referenced all cases and we updated the GNAS LOVD database. 
From this analysis we identified 132 GNAS mutations in PHP/PPHP patients, of 
which 116 previously reported plus our 16 novel mutations. Using this information we 
delineated an updated GNAS mutational spectrum, composed of 47% point mutations (37% 
missense, 10% nonsense), 39% frameshift (25% deletions, 14% insertions) and 13% affecting 
splicing (figure 2). To date, a single case of in-frame insertion has been reported.[12] 
Considering the distribution of the mutations within Gsα coding sequence, exon 1 is the most 
affected site, harbouring 16% of all GNAS mutations, followed by exon 10 (13%), exon 13 
(11%) and exons 4 and 5 (9% each). Moreover, also acceptor/donor splice sites show an high 
mutation rate, with a frequency of 13% in the overall PHP/PPHP population (figure 1).  
 
Genotype/phenotype correlation 
The patients were divided according to the presence of frameshift, missense, 
nonsense or intronic mutations and subsequently according to the affected functional 
domain. We then compared these different groups in terms of related clinical parameters 
(age at diagnosis; calcium, phosphorus, PTH and TSH levels; number of AHO signs). By 
this approach, neither the mutation type nor its location did correlate with the onset of the 
disease, the severity of endocrine resistances, or with the presence/absence of specific AHO 
signs (data not shown). 
 
DISCUSSION 
 The present study describes 48 patients affected with PHP-Ia or PPHP and carrying 
mutations in GNAS Gs-coding exons, who were diagnosed during the past decade in the two 
referring Italian Centers for these rare disorders, and reports 33 mutations, 16 of which are 
novel to the literature. 
The review of all published GNAS mutations (116 previously reported plus our 16 
novel mutations) in PHP/PPHP patients confirms that mutations are distributed throughout 
the entire gene and allowed us to delineate an updated GNAS mutational spectrum, with 47% 
point mutations (37% missense, 10% nonsense), 39% frameshift (25% deletions, 14% 
insertions) and 13% affecting splicing (figure 2).   
Most of the genetic defects here and elsewhere described are private mutations being 
confined to one or few patients. In our series, the only mutational hot-spot so far recognized, 
i.e. a 4-bp deletion in exon 7 (c.568_571delGACT) that removes a defined consensus 
sequence for DNA polymerase arrest, accounted for 5 unrelated patients (10.4 % of the 
patients described here). Our observation is in accordance with previous reports, confirming 
the presence of an hot spot in this region, though with a lower frequency than the one 
reported by others (up to 35 %) (table 2).[9]  
Few additional mutations have been found to recur in unrelated patients, so that the 
presence of identical de novo mutations probably derives from the presence of a common 
molecular mechanism rather than a founder effect (table 4).  
As known, the frequency of a given mutation is influenced by several phenomena, 
such as the size of the gene, the nucleotide sequence itself, and chemical changes (i.e. 
cytosine deamination is a frequent cause of C>T  transition).[36] Accordingly, in the present 
series we detected 2 novel mutations in exon 1, c.85C>T and c.103C>T, in 4 patients from 3 
different families. Interestingly, also two other alterations have been described in this exon 
that recurred in more than one kindred. In fact, c.1A>G and c.91C>T mutations were each 
detected in 3 patients belonging to 2 families.[5,13,14]   
Interestingly, we found 5 additional previously undetected mutations in exon 1 (c.1-
10_2delCGCCGCCGCCAT, c.7T>C, c.21_22insT, 97G>A, c.110delA), strongly suggesting 
the importance to carefully screen this exon, that is sometimes omitted being difficult to 
amplify due to the richness in guanosines and cytosines in its boundaries and that we now 
propose to consider as a new mutational hot spot. 
Importantly, the overall high frequency of mutations located in exon 1 further 
confirms the primary role of Gs protein deficiency in PHP/PPHP pathology, as exon 1 is the 
only GNAS exon encoding exclusively for Gsexons 2-13 being common also to NESP55 
and XLs genes/proteins. As resumed in figure 2, considering both known and novel 
mutations, exon 1 is the most frequent site of mutation representing 16% of all GNAS 
mutations, followed by exon 10 (13%), exon 13 (11%) and exons 4 and 5 (9% each). This 
observation is in accordance with the knowledge that these exons encode for crucial Gs 
functional domains (figure 1). Also intronic flanking sequences frequently bear mutations, as 
shown by the high frequency detected in the overall PHP population (13%) and further 
confirmed in our series in which we detected 2 novel splice site mutations (c.139+1T>A, 
c.258+1G>A).  
As suggested by previous observations including ours [11], no apparent difference 
was observed among patients harboring different types of mutations in terms of age at 
diagnosis (as marker of disease precocity and severity), number of AHO signs and number or 
severity of hormonal resistances, further confirming the absence of genotype/phenotype 
correlation in this disease and supporting the hypothesis of Gs haploinsufficiency as the 
molecular mechanism underlying PHP independently of the mutation type/extension/region 
(table 1).  
In conclusion, our results provide an estimate of the prevalence and the distribution of 
all GNAS mutations detected so far in PHP/PPHP patients and highlight both genetic and 
phenotypic heterogeneity among and within families. Furthermore, the present work provides 
an updated compilation of mutational and phenotypic data for both diagnostic and research 
purposes, as a step towards a better understanding of PHP. Indeed, we updated the GNAS 
Locus-Specific database (the database is available on the internet at 
http://chromium.liacs.nl/LOVD2/home.php?select_db=GNAS) with the hope that our 
commitment will promote the further contribution from all research scientists, physicians and 
diagnostic laboratories involved in GNAS screening and PHP management.   
 
Table 4 GNAS mutations found associated with PHP/PPHP phenotype in more than 1 
kindred and/or affecting the same amino acidic residue (highlighted by black boxes). The 4 
nucleotides deletion in exon 7 (in bold) is the more frequent defect so far detected, thus 
classically considered an hot spot. 
 
exon  DNA sequence change  amino acid change n°pts n°families 
1 c.1A>G p.(0)? 3 2 
1 c.85C>T p.(Gln29X) 4 3 
1 c.91C>T p.(Gln31X) 3 2 
1 c.103C>T p.(Gln35X) 5 3 
4 c.268delG p.(Ala90Glnfs*10) 1 1 
4 c.269_272delCAAC p.(Ala90Alafs*9) 1 1 
4 c.308C>A p.(Ala103Glu) 2 2 
4 c.308C>T p.(Ala103Val) 1 1 
4 c.311T>C p.(Ile104Thr) 2 2 
5 c.351delC p.(Pro115Profs*17) 2 2 
5 c.346C>T p.(Pro116Ser) 1 1 
5 c.347C>T p.(Pro116Leu) 2 2 
5 c.347_348insT p.(Pro116Profs*24) 2 2 
5 c.348_349insC p.(Val118Argfs*22) 2 2 
5i  c.435+1G>A  p.(?)  3  3  
6 c.478G>A p.(Val160Met) 2 2 
6 c.481C>T p.(Arg161Cys) 2 2 
6 c.496C>T p.(Arg166Cys) 2 2 
7 c.568_571delGACT p.(Asp190Metfs*13) 19 19 
9 c.681_682insC p.(Gln228Profs*3) 1 1 
9 c.683A>G p.(Gln228Arg) 2 2 
9 c.684G>(CorT) p.(Gln228His) 1 1 
10 c.728C>T p.(Thr243Ile) 2 2 
10 c.728delC p.(Thr243Metfs*28) 1 1 
10 c.841A>G p.(Arg281Gly) 1 1 
10 c.842G>A p.(Arg281Lys) 1 1 
10 c842insAACAG p.(Arg281Argfs*X) 1 1 
12 c.1109C>T p.(Arg337Trp) 2 2 
13 c.1110_1111delTG p.(Thr370Thrfs*11) 2 2 
13  c.1153C>T  p.(Gln385X)  3  2  
13 c.1166T>G p.(Leu389Arg) 1 1 
13 c.1166T>C p.(Leu389Pro) 1 1 
13 c.1177G>A p.(Glu393Lys) 1 1 
13 c.1177G>T p.(Glu393X) 7 6 
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FIGURE LEGENDS  
Figure 1  Schematic illustration of the GNAS gene and of all mutations found in PHP type A 
and PPHP phenotypes. On the left the novel mutations found in our series are represented. In 
the middle of the figure mutations already reported in locus-specific public databases are 
resumed. Each symbol represents a single mutation, regardless of the number of patients 
carrying it (♦ mutations in coding exons, * mutations in introns).   
Figure 2 Upper panel. Graph showing the mutational spectrum of GNAS Gs-coding gene. 
Lower panel. The figure shows the distribution of mutations associated with PHP/PPHP 
within the gene. The white bar represents known and novel mutations found in our series, the 
grey one indicates mutations collected in locus-specific databases and the black one the 
combination of all the above. Thus, the black bar is an intuitive representation of the 
distribution of all the mutations found so far demonstrating that the most affected regions are 
represented by exons 1 & 10 and the intronic flanking sequences, followed by exons 13, 4 
and 5. It is also of notice that the majority of novel mutations found in our patients are 
located in exon 1. 
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